Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 3/20 | 0.46 |
| ▸ | S100A4 | P26447 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30279963 | 1.00 | PTPRC (0.46) | PTPRCS100A4TDP1ALDH1A1CYP3A4 | |
| SCHEMBL3379806 | 0.85 | CYP1A2 (0.45) | PTPRCS100A4TDP1ALDH1A1CYP3A4 | |
| SCHEMBL30468473 | 0.85 | CYP1A2 (0.45) | PTPRCS100A4TDP1ALDH1A1CYP3A4 | |
| SCHEMBL13043154 | 0.85 | POLB (0.53) | PTPRCS100A4TDP1ALDH1A1CYP3A4 | |
| SCHEMBL260864 | 0.84 | CYP1A2 (0.47) | PTPRCS100A4TDP1ALDH1A1CYP3A4 | |
| SCHEMBL29368452 | 0.84 | CYP1A2 (0.47) | PTPRCS100A4TDP1ALDH1A1CYP3A4 | |
| SCHEMBL135919 | 0.83 | CA1 (0.45) | PTPRCS100A4TDP1ALDH1A1CYP3A4 | |
| SCHEMBL2860338 | 0.83 | TSHR (0.49) | PTPRCS100A4TDP1ALDH1A1CYP3A4 | |
| SCHEMBL2082256 | 0.83 | LOXL2 (0.50) | PTPRCS100A4TDP1ALDH1A1CYP3A4 | |
| SCHEMBL29706685 | 0.82 | PTPRC (0.52) | PTPRCS100A4TDP1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117917402-A | Isoindolylamide compound, and pharmaceutical composition and application thereof | 暨南大学 | 2024-04-23 | — | — | CN | disclosed |
| CN-117466897-A | Highly selective FGFR2 inhibitors | 深圳福沃药业有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20230203059-A1 | MACROCYCLIC JAK INHIBITOR AND USES THEREOF | BIOPOLAR HONGYE (NANTONG) PHARMACEUTICAL CO. LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| CN-109562111-B | CK2 inhibitors, compositions and methods thereof | 北极星药业股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3474855-B1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS INC (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2019189766-A1 | NOVEL BIARYL AMIDE DERIVATIVE | 持田製薬株式会社 | 2019-10-03 | — | — | WO | disclosed |
| EP-3474855-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Polaris Pharmaceuticals, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| CN-109562111-A | CK2 inhibitor, its composition and method | 北极星药业股份有限公司 | 2019-04-02 | — | — | CN | disclosed |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | POLARIS PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS | 2017-12-28 | — | — | US | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110172187-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011060196-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | PTPRC 2568/4885S100A4 3789/4885TDP1 1006/4885 |
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | CSNK1A1, CSNK2A1, CSNK2A3 | PTPRC 551/4885S100A4 874/4885TDP1 3636/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | PTPRC 2568/4885S100A4 3789/4885TDP1 1006/4885 |
| US-20110172187-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | PTPRC 1227/4885S100A4 1627/4885TDP1 2867/4885 |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | CSNK1A1, CSNK2A1, CSNK2A3 | PTPRC 551/4885S100A4 874/4885TDP1 3636/4885 |
| US-20230203059-A1 | MACROCYCLIC JAK INHIBITOR AND USES THEREOF | JAK3, JAK2, JAK1 | PTPRC 989/4885S100A4 3983/4885TDP1 3755/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | PTPRC 2568/4885S100A4 3789/4885TDP1 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.